Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
Ming Shen Dai, Yin Hsun Feng, Shang Wen Chen, Norikazu Masuda, Thomas Yau, Shou Tung Chen, Yen Shen Lu, Yoon Sim Yap, Peter C.S. Ang, Sung Chao Chu, Ava Kwong, Keun Seok Lee, Samuel Ow, Sung Bae Kim, Johnson Lin, Hyun Cheol Chung, Roger Ngan, Victor C. Kok, Kun Ming Rau, Takafumi SangaiTing Ying Ng, Ling Ming Tseng, Richard Bryce, Judith Bebchuk, Mei Chieh Chen, Ming Feng Hou
Dive into the research topics of 'Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens'. Together they form a unique fingerprint.